EPHA4

Ephrin type-A receptor 4 · P54764 · EPHA4 on Sugi Atlas →

15,395 patent compounds predicted against EPHA4, 12,729 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Trifluoroacetic Acid (SCHEMBL1074026)	0.46	5/20
Trifluoroacetic Acid (SCHEMBL1076362)	0.46	5/20
Dasatinib Anhydrous (SCHEMBL8226)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	2/20
Mln-8054 (SCHEMBL621589)	1.00	2/20
Alisertib (SCHEMBL855823)	1.00	2/20
Alisertib (SCHEMBL854553)	0.98	2/20
Dasatinib Anhydrous (SCHEMBL1363032)	0.94	2/20
Dasatinib Anhydrous (SCHEMBL1362204)	0.90	2/20
Alisertib (SCHEMBL854552)	0.86	2/20
SCHEMBL1147156	0.84	2/20
SCHEMBL1147171	0.84	2/20
SCHEMBL1146489	0.81	2/20
SCHEMBL1146496	0.81	2/20
SCHEMBL1147074	0.80	2/20
SCHEMBL1147022	0.79	2/20
SCHEMBL1147135	0.79	2/20
SCHEMBL1147164	0.79	2/20
SCHEMBL1147166	0.79	2/20
SCHEMBL231130	0.78	2/20

Clinical trials — most relevant to EPHA4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants	PHASE4	COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
IL-2 in Refractory Autoimmune Encephalitis	PHASE1/PHASE2	COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye	PHASE2	COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Susceptibility Genes in Autism Spectrum Disorders	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Reference Values of Intraepidermal Nerve Fiber Density in Children and Small Fiber Neuropathy in Neurodevelopmental Disorders	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Genetics of Arteriovenous Malformations	nan	UNKNOWN
Phenotypic Exploration of Autism Spectrum Disorders Retrospective and Prospective Data	nan	RECRUITING
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)	nan	RECRUITING
Brain Imaging in Alzheimer's Disease	nan	COMPLETED
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
Spinal Cord Stimulation for Spinal Cord Injury Patients - Regain Walk and Alleviate Pain	nan	RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children	nan	COMPLETED
Epidural Electrical Stimulation for Spinal Cord Injury Patients and Corticospinal Motor Circuit Improvement	nan	RECRUITING
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention Deficit Hyperactivity Disorder (ADHD)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EPHA4 binder may also engage these)

Protein	Name	Similarity
Q03137	—	1.000	Q03137 →
Q90344	—	1.000	Q90344 →
Q91694	—	1.000	Q91694 →
Q07496	—	1.000	Q07496 →
Q07498	—	1.000	Q07498 →
Q91845	—	1.000	Q91845 →
EPHA3	Ephrin type-A receptor 3	1.000	landscape →
Q91735	—	1.000	Q91735 →
O42422	—	1.000	O42422 →
P54757	—	1.000	P54757 →
Q60629	—	0.999	Q60629 →
Q8CBF3	—	0.999	Q8CBF3 →
Q07497	—	0.999	Q07497 →
EPHA5	Ephrin type-A receptor 5	0.998	landscape →
Q03145	—	0.998	Q03145 →
Q91736	—	0.998	Q91736 →
P09759	—	0.998	P09759 →
P54755	—	0.998	P54755 →
EPHA6	Ephrin type-A receptor 6	0.998	landscape →
O08680	—	0.998	O08680 →
P54763	—	0.997	P54763 →
Q91571	—	0.997	Q91571 →
P54759	—	0.996	P54759 →
P29319	—	0.996	P29319 →
P29318	—	0.996	P29318 →
EPHB1	Ephrin type-B receptor 1	0.996	landscape →
EPHB2	Ephrin type-B receptor 2	0.996	landscape →
Q62413	—	0.995	Q62413 →
EPHA7	Ephrin type-A receptor 7	0.995	landscape →
Q1KL86	—	0.995	Q1KL86 →